Structure Therapeutics(US:GPCR)2024-11-13 21:10Financial Position - Structure Therapeutics reported a cash position of $915.3 million as of September 30, 2024, expected to fund operations through at least 2027[8]. Research and Development Expenses - Research and Development (R&D) expenses for Q3 2024 were $32.6 million, a 86% increase from $17.5 million in Q3 2023[9]. - The Phase 2b ACCESS study of GSBR-1290 for obesity has begun dosing the first patients, with topline data expected in Q4 2025[4]. - The ACCESS study aims to enroll approximately 220 adults and evaluate doses up to 120 mg over 36 weeks[3]. - The ACCESS II study plans to enroll about 82 adults and evaluate higher doses of 180 mg and 240 mg over 36 weeks[4]. - Structure Therapeutics expects to select its first oral small molecule amylin development candidate by the end of 2024[2]. - The company is also developing a GIPR selective agonist and GLP-1R/GIPR combinations, with a candidate selection expected in the first half of 2025[6]. Operating Expenses - General and Administrative (G&A) expenses for Q3 2024 were $13.2 million, up 53% from $8.6 million in Q3 2023[10]. - Total operating expenses for Q3 2024 were $45.8 million, compared to $26.1 million in Q3 2023, reflecting a 75% increase[15]. Net Loss - The net loss for Q3 2024 was $34.0 million, compared to a net loss of $23.9 million in Q3 2023[11].